Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Canada OKs silicone implants

This article was originally published in The Gray Sheet

Executive Summary

Allergan and Mentor receive medical device licenses from Health Canada for their silicone gel-filled breast implants Oct. 20. The licenses for Allergan's Inamed round, smooth and textured implants, Inamed Style 410 shaped and textured implants, and Mentor's MemoryGel round and CPG contour implants come with a number of conditions, including that the firms begin long-term studies of tens of thousands of women and conduct focus groups of patients and plastic surgeons related to product labeling, all within one year. As in the U.S., silicone gel-filled breast implants previously were available only on a restricted basis in Canada. Both firms are still awaiting FDA go-ahead for the products after receiving "approvable" letters in 2005 (1"The Gray Sheet" Sept. 26, 2005, p. 17)...

You may also be interested in...



Inamed Receives Silicone Breast Implant “Approvable” Letter From FDA

Inamed's silicone gel-filled breast implants inched closer to the market with the receipt of an FDA "approvable" letter, after the firm removed the controversial Style 153 implants from its PMA application

Sandoz Launches US Awareness Campaign

Sandoz has launched an awareness campaign under the banner of “Ask For Generics” in the US. The initiative is aiming to educate stakeholders on the benefits of generics and their quality, safety and efficacy.

EU Plans IP Law Shake-Up

European Commission proposals for strengthening intellectual property protections in the EU, particularly the supplementary protection certificate (SPC) system, have been broadly welcomed by Europe’s brand industry. But the medical NGO, MSF, says the SPC proposals run counter to the commission’s own efforts to improve access to medicines.

UsernamePublicRestriction

Register

LL026487

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel